Clinical trials: Placebo Group
Chronic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine.
- Trial name
- C-BEOND (NCT06047444)
- Testing
- Botulinum toxin type A
- Where
- 120 sites in United States, Canada and 7 more
- Volunteers
- 759 people
- Sponsor
- Ipsen
Erectile Dysfunction
Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction
Study to investigate the efficacy and safety of Vardenafil
- Trial name
- NCT00658177
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Volunteers
- 463 people
- Sponsor
- Bayer
Dental Pain
Study of Diclofenac Capsules to Treat Dental Pain
The purpose of this study is to determine whether Diclofenac Test Formulation Capsules are safe and effective for the treatment of dental pain.
- Trial name
- NCT00985439
- Testing
- Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib 400 mg
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Iroko Pharmaceuticals, LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
- Trial name
- NCT00838903
- Testing
- albiglutide, sitagliptin, glimepiride
- Where
- 386 sites in United States, Albania and 9 more
- Volunteers
- 1,049 people
- Sponsor
- GlaxoSmithKline
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
The purpose of this study is to evaluate the efficacy and safety of SYH2053 monotherapy in patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia . This trial plans to enroll 760 Participants.
- Trial name
- NCT07421297
- Testing
- SYH2053 injection
- Where
- 2 sites in China
- Volunteers
- 760 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
Antibiotic-associated Diarrhea
Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.
The goal of this study was to investigate the efficacy and safety of LRG-002 investigational medicinal product, capsules (Lek d.d., Slovenia) in comparison with placebo, as an adjunct treatment for prophylaxis of…
- Trial name
- NCT04321460
- Testing
- LRG-002
- Where
- 3 sites in Russia
- Volunteers
- 520 people
- Sponsor
- Sandoz
Alzheimer Disease
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00667810
- Testing
- bapineuzumab
- Where
- 346 sites in United States, Argentina and 24 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Bacterial Infections
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion in healthy subjects.
- Trial name
- NCT02955459
- Testing
- VNRX-5133
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Venatorx Pharmaceuticals, Inc.
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Schizophrenia, Schizophrenia; Psychosis
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and…
- Trial name
- NCT04738123
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 32 sites in United States, Ukraine
- Volunteers
- 256 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Type 2 Diabetes
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00918879
- Testing
- Saxagliptin
- Where
- 9 sites in India
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Healthy Population
A Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.
The present study is a randomized, placebo-controlled, parallel study. 250 participants will be screened, and considering a screening failure rate of 20%, approximately 200 participants will be randomized in a ratio of 1:1:1:1:1…
- Trial name
- NCT06473246
- Testing
- CBD Isolate (25 mg/0.5 ml), CBD Isolate (40 mg/0.5 ml), CBD Isolate (50 mg/0.5 ml)
- Where
- 6 sites in India
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Pain, Postoperative
Phase 3 Efficacy and Safety Study of VVZ-149 Injections for Postoperative Pain Following Bunionectomy
The purpose of this phase 3 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections for treating post-operative pain following bunionectomy.
- Trial name
- NCT04430088
- Testing
- VVZ-149 Injections
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Vivozon, Inc.
Oral Mucositis
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy.
- Trial name
- NCT00289003
- Testing
- Soluble beta-1,3/1,6-glucan
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Biotec Pharmacon ASA
Rheumatoid Arthritis
Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
To assess the clinical efficacy and safety of certolizumab pegol as add-on therapy with stable-dose disease-modifying antirheumatic drugs (DMARDs) for achieving clinical remission in patients with moderate to low disease activity…
- Trial name
- CERTAIN (NCT00674362)
- Testing
- Certolizumab pegol
- Where
- 31 sites in Austria, France and 3 more
- Volunteers
- 194 people
- Sponsor
- UCB Pharma
Healthy
Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects
The purpose of this study is to determine how well tolerated and safe AZD5069 is at different dose levels in healthy male and/or females.
- Trial name
- NCT00953888
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who…
- Trial name
- NCT01970046
- Testing
- SP2086 50 mg b.i.d/Metformin, SP2086 50 mg q.d./Metformin
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects
To investigate the safety, tolerability and pharmacokinetics of BI 425809 tablets in healthy Chinese and Japanese male subjects following the administration of single rising oral doses and further to explore the pharmacokinetics…
- Trial name
- NCT02383888
- Testing
- BI 425809
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
- Trial name
- MAPUS (NCT01951326)
- Testing
- RHB-104
- Where
- 103 sites in United States, Australia and 8 more
- Volunteers
- 331 people
- Sponsor
- RedHill Biopharma Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.